Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Kantarjian, Hagop M  [Clear All Filters]
Journal Article
Maiti, A., Kantarjian, H.M., Popat, V., Borthakur, G., Garcia-Manero, G., Konopleva, M.Y., Dinardo, C.D., Verstovsek, S., Andreeff, M., Kadia, T.M., et al. (2020). Clinical value of event-free survival in acute myeloid leukemia.Blood Adv4, 1690-1699.
Ravandi, F., Jorgensen, J.L., Thomas, D.A., O'Brien, S., Garris, R., Faderl, S., Huang, X., Wen, S., Burger, J.A., Ferrajoli, A., et al. (2013). Detection of MRD may predict the outcome of patients with Philadelphia-chromosome positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.Blood.
Jain, N., Lamb, A.E., O'Brien, S., Ravandi, F., Konopleva, M., Jabbour, E., Zuo, Z., Jorgensen, J., Lin, P., Pierce, S., et al. (2016). Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.Blood.
Stein, E.M., Fathi, A.T., Dinardo, C.D., Pollyea, D.A., Roboz, G.J., Collins, R., Sekeres, M.A., Stone, R.M., Attar, E.C., Frattini, M.G., et al. (2020). Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.Lancet Haematol.
Ravandi, F., Assi, R., Daver, N., Benton, C.B., Kadia, T., Thompson, P.A., Borthakur, G., Alvarado, Y., Jabbour, E.J., Konopleva, M., et al. (2019). Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.Lancet Haematol.
Kantarjian, H.M., DeAngelo, D.J., Stelljes, M., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S.M., Jabbour, E., Wang, T., White, J.Liang, et al. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.Cancer.
Ravandi, F., Jorgensen, J.L., O'Brien, S.M., Jabbour, E., Thomas, D.A., Borthakur, G., Garris, R., Huang, X., Garcia-Manero, G., Burger, J.A., et al. (2015). Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.Br J Haematol.
Dalle, I.Abou, Kantarjian, H.M., Short, N.J., Konopleva, M., Jain, N., Garcia-Manero, G., Garris, R., Qiao, W., Cortes, J.E., O'Brien, S., et al. (2019). Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.Am J Hematol.
Zuo, Z., Maiti, S., Hu, S., Loghavi, S., Calin, G.A., Garcia-Manero, G., Kantarjian, H.M., L Medeiros, J., Cooper, L.Jn, and Bueso-Ramos, C.E. (2014). Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes.Mod Pathol.
Oran, B., Garcia-Manero, G., Saliba, R.M., Alfayez, M., Al-Atrash, G., Ciurea, S.O., Jabbour, E.J., Mehta, R.S., Popat, U.R., Ravandi, F., et al. (2020). Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.Cancer.
Short, N.J., Kantarjian, H.M., Sasaki, K., Cortes, J.E., Ravandi, F., Thomas, D.A., Garcia-Manero, G., Khouri, I., Kebriaei, P., Champlin, R.E., et al. (2016). Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.Cancer.
Han, L., Qiu, P., Zeng, Z., Jorgensen, J.L., Mak, D.H., Burks, J.K., Schober, W., McQueen, T.J., Cortes, J., Tanner, S.D., et al. (2015). Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.Cytometry A.
Sasaki, K., Kantarjian, H.M., Kadia, T., Patel, K., Loghavi, S., Garcia-Manero, G., Jabbour, E.J., DiNardo, C., Pemmaraju, N., Daver, N., et al. (2019). Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.Cancer.
Ma, H., Mallampati, S., Lu, Y., Sun, B., Wang, E., Leng, X., Gong, Y., Shen, H., Yin, C.Cameron, Jones, D., et al. (2014). Sox4/Tcf7l1 axis promotes progression of BCR- ABL+ acute lymphoblastic leukemia.Haematologica.
Carter, B.Z., Mak, P.Yee, Mak, D.H., Ruvolo, V.R., Schober, W., McQueen, T., Cortes, J., Kantarjian, H.M., Champlin, R.E., Konopleva, M., et al. (2015). Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.Oncotarget.
Pemmaraju, N., Lane, A.A., Sweet, K.L., Stein, A.S., Vasu, S., Blum, W., Rizzieri, D.A., Wang, E.S., Duvic, M., J Sloan, M., et al. (2019). Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.N Engl J Med380, 1628-1637.
Jabbour, E.J., Gökbuget, N., Kantarjian, H.M., Thomas, X., Larson, R.A., Yoon, S.-S., Ghobadi, A., Topp, M.S., Tran, Q., Franklin, J.L., et al. (2019). Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.Cancer.
Martinelli, G., Oehler, V.G., Papayannidis, C., Courtney, R., M Shaik, N., Zhang, X., O'Connell, A., McLachlan, K.R., Zheng, X., Radich, J., et al. (2015). Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.Lancet Haematol2, e339-46.